{"pmid":32369609,"title":"Thrombocytopenia as an initial manifestation of Covid-19; Case Series and Literature review.","text":["Thrombocytopenia as an initial manifestation of Covid-19; Case Series and Literature review.","Covid-19 has emerged as a global threat that has claimed millions of lives until now. Haematological manifestation as an initial presentation of this deadly virus is not frequently reported in the literature. We hereby report a case series of asymptomatic patients with severe thrombocytopenia which was later found to be Covid induced.","Br J Haematol","Ahmed, Maria Zahid","Khakwani, Muhammad","Venkatadasari, Indrani","Horgan, Claire","Giles, Hannah","Jobanputra, Shailesh","Lokare, Anand","Ewing, Joanne","Shankara, Paneesha","Murthy, Vidhya","32369609"],"abstract":["Covid-19 has emerged as a global threat that has claimed millions of lives until now. Haematological manifestation as an initial presentation of this deadly virus is not frequently reported in the literature. We hereby report a case series of asymptomatic patients with severe thrombocytopenia which was later found to be Covid induced."],"journal":"Br J Haematol","authors":["Ahmed, Maria Zahid","Khakwani, Muhammad","Venkatadasari, Indrani","Horgan, Claire","Giles, Hannah","Jobanputra, Shailesh","Lokare, Anand","Ewing, Joanne","Shankara, Paneesha","Murthy, Vidhya"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369609","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16769","locations":["thrombocytopenia","Thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1666138496213975040,"score":9.490897,"similar":[{"pmid":32420612,"title":"COVID-19-associated immune thrombocytopenia.","text":["COVID-19-associated immune thrombocytopenia.","Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection.","Br J Haematol","Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G","32420612"],"abstract":["Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS-CoV-2 infection (COVID-19 infection).(1) Thrombocytopenia in COVID-19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug-induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID-19 infection.(2) ITP is a rare autoimmune disease characterized by a platelet count < 100x10(9) /L, leading to an increased bleeding risk.(3) Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.(4) We report here the first case series of three patients with ITP associated with COVID-19 infection."],"journal":"Br J Haematol","authors":["Bomhof, G","Mutsaers, P G N J","Leebeek, F W G","Te Boekhorst, P A W","Hofland, J","Croles, F N","Jansen, A J G"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420612","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bjh.16850","locations":["Thrombocytopenia","Thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1667254896710123520,"score":107.877556},{"pmid":32381430,"pmcid":"PMC7189855","title":"Cutaneous manifestations of COVID-19: Report of three cases and a review of literature.","text":["Cutaneous manifestations of COVID-19: Report of three cases and a review of literature.","BACKGROUND: Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, overall similarities in the clinical presentation of these dermatological manifestations have not yet been summarized. OBJECTIVE: This review aims to provide an overview of various cutaneous manifestations in patients with COVID-19 through three case reports and a literature review. METHODS: A literature search was conducted using PubMed, OVID, and Google search engines for original and review articles. Studies written in the English language that mentioned cutaneous symptoms and COVID-19 were included. RESULTS: Eighteen articles and three additional cases reported in this paper were included in this review. Of these studies, 6 are case series and 12 are case report studies. The most common cutaneous manifestation of COVID-19 was found to be maculopapular exanthem (morbilliform), presenting in 36.1% (26/72) patients. The other cutaneous manifestations included: a papulovesicular rash (34.7%, 25/72), urticaria (9.7%, 7/72), painful acral red purple papules (15.3%, 11/72) of patients, livedo reticularis lesions (2.8%, 2/72) and petechiae (1.4%, 1/72). Majority of lesions were localized on the trunk (66.7%, 50/72), however, 19.4% (14/72) of patients experienced cutaneous manifestations in the hands and feet. Skin lesion development occurred before the onset of respiratory symptoms or COVID-19 diagnosis in 12.5% (9/72) of the patients, and lesions spontaneously healed in all patients within 10 days. Majority of the studies reported no correlation between COVID-19 severity and skin lesions. CONCLUSION: Infection with COVID-19 may result in dermatological manifestations with various clinical presentations, which may aid in the timely diagnosis of this infection.","J Dermatol Sci","Sachdeva, Muskaan","Gianotti, Raffaele","Shah, Monica","Lucia, Bradanini","Tosi, Diego","Veraldi, Stefano","Ziv, Michael","Leshem, Eyal","Dodiuk-Gad, Roni P","32381430"],"abstract":["BACKGROUND: Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, overall similarities in the clinical presentation of these dermatological manifestations have not yet been summarized. OBJECTIVE: This review aims to provide an overview of various cutaneous manifestations in patients with COVID-19 through three case reports and a literature review. METHODS: A literature search was conducted using PubMed, OVID, and Google search engines for original and review articles. Studies written in the English language that mentioned cutaneous symptoms and COVID-19 were included. RESULTS: Eighteen articles and three additional cases reported in this paper were included in this review. Of these studies, 6 are case series and 12 are case report studies. The most common cutaneous manifestation of COVID-19 was found to be maculopapular exanthem (morbilliform), presenting in 36.1% (26/72) patients. The other cutaneous manifestations included: a papulovesicular rash (34.7%, 25/72), urticaria (9.7%, 7/72), painful acral red purple papules (15.3%, 11/72) of patients, livedo reticularis lesions (2.8%, 2/72) and petechiae (1.4%, 1/72). Majority of lesions were localized on the trunk (66.7%, 50/72), however, 19.4% (14/72) of patients experienced cutaneous manifestations in the hands and feet. Skin lesion development occurred before the onset of respiratory symptoms or COVID-19 diagnosis in 12.5% (9/72) of the patients, and lesions spontaneously healed in all patients within 10 days. Majority of the studies reported no correlation between COVID-19 severity and skin lesions. CONCLUSION: Infection with COVID-19 may result in dermatological manifestations with various clinical presentations, which may aid in the timely diagnosis of this infection."],"journal":"J Dermatol Sci","authors":["Sachdeva, Muskaan","Gianotti, Raffaele","Shah, Monica","Lucia, Bradanini","Tosi, Diego","Veraldi, Stefano","Ziv, Michael","Leshem, Eyal","Dodiuk-Gad, Roni P"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381430","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jdermsci.2020.04.011","keywords":["covid-19","cutaneous manifestations","review","skin"],"topics":["Case Report"],"weight":1,"_version_":1666419683361816576,"score":93.713234},{"pmid":32342677,"title":"Severe Thrombocytopenia in a Patient with COVID-19.","text":["Severe Thrombocytopenia in a Patient with COVID-19.","Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.","Infect Chemother","Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran","32342677"],"abstract":["Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm(3) and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered."],"journal":"Infect Chemother","authors":["Nham, Eliel","Ko, Jae Hoon","Jeong, Byeong Ho","Huh, Kyungmin","Cho, Sun Young","Kang, Cheol In","Chung, Doo Ryeon","Peck, Kyong Ran"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342677","source":"PubMed","week":"202018|Apr 27 - May 03","keywords":["covid-19","ceftriaxone, levofloxacin","lopinavir/ritonavir","thrombocytopenia"],"locations":["Thrombocytopenia"],"e_drugs":["Ceftriaxone","lopinavir-ritonavir drug combination","Levofloxacin"],"topics":["Case Report"],"weight":1,"_version_":1666138495809224708,"score":92.788704},{"pmid":32483524,"pmcid":"PMC7255984","title":"Isolated severe thrombocytopenia in a patient with COVID-19: A case report.","text":["Isolated severe thrombocytopenia in a patient with COVID-19: A case report.","COVID-19 is known to cause serious respiratory symptoms and involvement of other body systems such as hematopoietic, neurological and the immune system. In this report, we described a case of a COVID-19 patient who presented with no pulmonary involvement but severe thrombocytopenia. She suffered from headache and malaise with no respiratory symptoms, fever or chills. Chest radiological imaging was unremarkable but, the laboratory results showed significant thrombocytopenia associated with relatively decreased lymphocytes. Based on her high-risk work environment, a reverse transcription polymerase chain reaction (RT-PCR) test was performed and SARS-CoV-2 RNA was detected in the nasopharyngeal swab. Complete blood count (CBC) of patient was re-checked during admission and platelet count showed rising trend up to normal levels. A narrow diagnostic approach where only febrile patients with pulmonary symptoms are evaluated for a COVID-19 diagnosis will result in many missed diagnoses; so it is important that physicians are familiar with atypical and rare presentations of COVID-19, such as isolated thrombocytopenia.","IDCases","Sadr, Sara","SeyedAlinaghi, SeyedAhmad","Ghiasvand, Fereshteh","Hassan Nezhad, Malihe","Javadian, Nina","Hossienzade, Roghieh","Jafari, Fatemeh","32483524"],"abstract":["COVID-19 is known to cause serious respiratory symptoms and involvement of other body systems such as hematopoietic, neurological and the immune system. In this report, we described a case of a COVID-19 patient who presented with no pulmonary involvement but severe thrombocytopenia. She suffered from headache and malaise with no respiratory symptoms, fever or chills. Chest radiological imaging was unremarkable but, the laboratory results showed significant thrombocytopenia associated with relatively decreased lymphocytes. Based on her high-risk work environment, a reverse transcription polymerase chain reaction (RT-PCR) test was performed and SARS-CoV-2 RNA was detected in the nasopharyngeal swab. Complete blood count (CBC) of patient was re-checked during admission and platelet count showed rising trend up to normal levels. A narrow diagnostic approach where only febrile patients with pulmonary symptoms are evaluated for a COVID-19 diagnosis will result in many missed diagnoses; so it is important that physicians are familiar with atypical and rare presentations of COVID-19, such as isolated thrombocytopenia."],"journal":"IDCases","authors":["Sadr, Sara","SeyedAlinaghi, SeyedAhmad","Ghiasvand, Fereshteh","Hassan Nezhad, Malihe","Javadian, Nina","Hossienzade, Roghieh","Jafari, Fatemeh"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483524","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.idcr.2020.e00820","keywords":["coronavirus disease 2019 (covid-19)","lymphopenia","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)","thrombocytopenia"],"topics":["Case Report"],"weight":1,"_version_":1668704334431387648,"score":86.89227},{"pmid":32305249,"pmcid":"PMC7159860","title":"A case of COVID-19 patient with the diarrhea as initial symptom and literature review.","text":["A case of COVID-19 patient with the diarrhea as initial symptom and literature review.","Since Dec 2019, a cluster of pneumonia outbreak in Wuhan, Hubei province, China, and soon spread to all province of China. The pathogen was proved to be a novel betacoronavirus called 2019 novel coronavirus (officially named by the World Health Organization as COVID-19). The typical clinical manifestations were fever, cough, dyspnea, and myalgia or fatigue. Less common symptoms included headache, diarrhea, nausea and vomiting. However diarrhea as the first symptom is rarely reported. Here we reported a case of 2019 novel coronavirus-infected patient (NCIP) with diarrhea as the initial symptom. Image of CT scan and laboratory examination and careful collected as well as detection of viral RNA in pharynx. The case demonstrate that gastrointestinal symptoms ware not rare in NCIP, and diarrhea could be the initial symptom.","Clin Res Hepatol Gastroenterol","Yang, Xiaodong","Zhao, Jie","Yan, Qiang","Zhang, Shangxin","Wang, Yigao","Li, Yongxiang","32305249"],"abstract":["Since Dec 2019, a cluster of pneumonia outbreak in Wuhan, Hubei province, China, and soon spread to all province of China. The pathogen was proved to be a novel betacoronavirus called 2019 novel coronavirus (officially named by the World Health Organization as COVID-19). The typical clinical manifestations were fever, cough, dyspnea, and myalgia or fatigue. Less common symptoms included headache, diarrhea, nausea and vomiting. However diarrhea as the first symptom is rarely reported. Here we reported a case of 2019 novel coronavirus-infected patient (NCIP) with diarrhea as the initial symptom. Image of CT scan and laboratory examination and careful collected as well as detection of viral RNA in pharynx. The case demonstrate that gastrointestinal symptoms ware not rare in NCIP, and diarrhea could be the initial symptom."],"journal":"Clin Res Hepatol Gastroenterol","authors":["Yang, Xiaodong","Zhao, Jie","Yan, Qiang","Zhang, Shangxin","Wang, Yigao","Li, Yongxiang"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305249","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.clinre.2020.03.013","keywords":["diarrhea","novel coronavirus"],"locations":["Wuhan","Hubei","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138493354508289,"score":80.07328}]}